Nicole S. White Sells 1,255 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) insider Nicole S. White sold 1,255 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $12.71, for a total transaction of $15,951.05. Following the sale, the insider now owns 13,025 shares in the company, valued at approximately $165,547.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Assembly Biosciences Stock Performance

ASMB stock opened at $13.15 on Friday. The stock’s fifty day moving average price is $13.23 and its 200-day moving average price is $11.19. Assembly Biosciences, Inc. has a 1 year low of $7.69 and a 1 year high of $20.04.

Institutional Trading of Assembly Biosciences

An institutional investor recently bought a new position in Assembly Biosciences stock. Marquette Asset Management LLC acquired a new position in Assembly Biosciences, Inc. (NASDAQ:ASMB) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned approximately 0.08% of Assembly Biosciences at the end of the most recent reporting period. 19.92% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ASMB. StockNews.com raised Assembly Biosciences from a “sell” rating to a “hold” rating in a research report on Friday, April 5th. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research note on Monday, April 1st.

About Assembly Biosciences

Assembly Biosciences, Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study.